These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7215416)

  • 21. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.
    Karim A; Kook C; Campion J; Doherty M
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disopyramide pharmacokinetics and bioavailability.
    Dubetz DK; Brown NN; Hooper WD; Eadie MJ; Tyrer JH
    Br J Clin Pharmacol; 1978 Sep; 6(3):279-81. PubMed ID: 687507
    [No Abstract]   [Full Text] [Related]  

  • 27. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
    Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
    Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.
    Hulting J; Jansson B
    Eur J Clin Pharmacol; 1977 Jan; 11(2):91-9. PubMed ID: 320015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-hemodynamic studies of disopyramide.
    Abdollah H; Brien JF; Armstrong PW
    J Cardiovasc Pharmacol; 1984; 6(1):28-34. PubMed ID: 6199608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
    Elliott HL; Thomson AH; Bryson SM
    Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
    De Graeve J; Kremers P; Gielen JE
    Therapie; 1977; 32(2):195-204. PubMed ID: 898127
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
    Aso R; Ohashi K; Katoh T; Ogata H
    Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Action of injected disopyramide on ventricular arrhythmias and atrioventricular conduction].
    Vogel M; Desoutter P; Bellanger P; Motté G; Welti JJ
    Arch Mal Coeur Vaiss; 1976 Apr; 69(4):395-406. PubMed ID: 59581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1979; 205(5):417-23. PubMed ID: 443082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of oral disopyramide therapy on left ventricular function.
    Greene AC; Iskandrian AS; Hakki AH; Kane SA; Segal BL
    Chest; 1983 Mar; 83(3):480-4. PubMed ID: 6825481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical pharmacology of disopyramide].
    Rewerski W; Dorociak A; Walczak F; Dobiasz A
    Pol Tyg Lek; 1980 Jul; 35(29):1109-12. PubMed ID: 7001399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.